With GPU acceleration becoming a fundamental feature in many HPC facilities, significant development work has been undertaken to allow HemeLB to run on a variety of new generation hardware. With efforts led by Dr Ioannis Zacharoudiou (UCL) and with support from partners across Europe and USA including CompBioMed2 consortium members SURF, Atos and Leibniz Supercomputing Centre (LRZ), Jülich Supercomputing Centre (JSC) and Oak Ridge National Laboratory, we are developing capability to run HemeLB on NVIDIA, AMD and Intel GPUs.
In a recent publication in Computer Physics Communications the CUDA based version is discussed. This paper highlights that the strong scaling characteristics of the CPU version have been retained in this GPU version with this observed on over 18,000 GPUs on the Summit supercomputer in USA.